




CYSTIC FIBROSIS (CF)

Genetics and pathogenesis


- mutations affecting a gene on the long arm of chromosome 7
- the gene codes for a chloride channel known as cystic fibrosis transmembrane conductance regulator (*CFTR*)
- (*CFTR*) influences salt and water movement across epithelial cell membranes.
- increased sodium and chloride content in sweat
- increased resorption of sodium and water from respiratory epithelium
- dehydration of the airway epithelium predisposes to chronic bacterial infection and ciliary dysfunction, leading to bronchiectasis.

Cystic fibrosis: basic defect in the pulmonary epithelium

A Normal



B Cystic fibrosis



Clinical findings

❑ transport dysfunction:

- thick secretions from exocrine glands
(lung, pancreas, skin, gonads)
- blockage of secretory ducts

❑ results in :

- severe lung disease
- pancreatic insufficiency
- azoospermia
(Most men with CF are infertile due to failure of development of the vas deferens)

❑ presents in childhood with recurrent lung infections that become persistent and chronic lead to bronchiectasis in childhood

❑ chronic lung infections

- *S. Aureus*: early
- *P. aeruginosa*: most common
- *Burkholderia cepacia* : worse prognosis but less common
- aspergillosis (benign 'colonisers' do not require specific therapy).

Clinical findings

- allergic bronchopulmonary aspergillosis
- coexistent asthma

Complications of cystic fibrosis

Respiratory

- Infective exacerbations of bronchiectasis
- Spontaneous pneumothorax
- Haemoptysis
- Nasal polyps
- Respiratory failure
- Cor pulmonale
- Lobar collapse due to secretions

Gastrointestinal

- Malabsorption and steatorrhoea
- Distal intestinal obstruction syndrome
- Biliary cirrhosis and portal hypertension
- Gallstones

Others

- Diabetes (25% of adults)
- Delayed puberty
- Male infertility
- Stress incontinence due to repeated forced cough
- Psychosocial problems
- Osteoporosis
- Arthropathy
- Cutaneous vasculitis

Investigations

❑ **sweat chloride test**

- increased concentrations of sodium, chloride, and potassium > 60 mmol/L is diagnostic in children
- heterozygotes have normal sweat tests (and no symptoms)

❑ **PFTs**

- characteristic of obstructive airway disease
- early: only small airways will be affected
- later: characteristics of obstructive disease with airflow limitation, hyperinflation, decreased Dco

❑ **ABGs**

- hypoxemia, hypercapnia later in disease with eventual respiratory failure and cor pulmonale

Investigations

❏ CXR

- hyperinflation
- increased pulmonary markings
- bronchiectasis

Treatment

- ❑ chest physio and postural drainage
- ❑ bronchodilators (ventolin +/- atrovent)
- ❑ inhaled DNase (reduces mucus viscosity)
- ❑ antibiotics (e.g. ciprofloxacin)
- ❑ Regular nebulised antibiotic therapy (colomycin or tobramycin) is used between exacerbations in an attempt to suppress chronic *Pseudomonas* infection.
- ❑ lung transplant

Treatments that may reduce chest exacerbations and/or improve lung function in CF

Therapy	Patients treated
Nebulised recombinant human DNase 2.5 mg daily	Age ≥ 5 , FVC $> 40\%$ predicted
Nebulised tobramycin 300 mg 12-hourly, given in alternate months	Patients colonised with <i>Pseudomonas aeruginosa</i>
Regular oral azithromycin 500 mg three times/week	Patients colonised with <i>Pseudomonas aeruginosa</i>

● **DNase** البشري إرذاذاً لحل الحمض النووي للخلايا الالتهابية
المخرّبة المسؤولة عن لزوجة المفرزات

Treatment of non-respiratory manifestations of CF

- Malabsorption :
oral pancreatic enzyme supplements and vitamins.
- Diabetes (25% of patients)often requires insulin therapy

Prognosis

- ❑ median survival age is 31 years for males and 30.5 for females
- ❑ death usually due to lung disease
(pneumonia, respiratory failure, cor pulmonale)